Does the primary treatment sequence affect post‐relapse survival in recurrent epithelial ovarian cancer? A real‐world multicentre retrospective study

Abstract

To explore the impact of the primary treatment sequence (primary debulking surgery, PDS, versus neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) on post-relapse survival (PRS) and recurrence characteristics of recurrent epithelial ovarian cancer (REOC). Real-world retrospective study. Tertiary hospitals in China. A total of 853 patients with REOC at International Federation of Gynaecology and Obstetrics stages IIIC-IV from September 2007 to June 2020. Overall, 377 and 476 patients received NACT-IDS and PDS, respectively. Propensity score-based inverse probability of treatment weighting (IPTW) was performed to balance the between-group differences. Clinicopathological factors related to PRS. The overall median PRS was 29.3months (95%CI 27.0-31.5months). Multivariate analysis before and after IPTW adjustment showed that NACT-IDS and residual R1/R2 disease were independent risk factors for PRS (p < 0.05). Patients with diffuse carcinomatosis and platinum-free interval (PFI) ≤ 12 months had a significantly worse PRS (p < 0.001). Logistic regression analysis revealed that NACT-IDS was an independent risk factor for diffuse carcinomatosis (OR1.36, 95%CI 1.01-1.82, p=0.040) and PFI ≤ 12 months (OR1.59, 95%CI 1.08-2.35, p=0.019). In IPTW analysis, NACT-IDS was still significantly associated with diffuse carcinomatosis (OR1.29, 95%CI 1.05-1.58, p=0.015) and PFI ≤ 12 months (OR1.90, 95%CI 1.52-2.38, p < 0.001). The primary treatment sequence may affect the PRS of patients with REOC by altering the recurrence pattern and PFI duration.